Although the World Health Organization (WHO) classification has incorporated molecular markers, such as isocitrate dehydrogenase (IDH) mutation, chromosome 1p/19q codeletion, and TERT promoter mutation, which has greatly improved the stratification of glioma patients (Louis et al., 2016), the heterogeneity of gliomas still needs to be further elucidated. This evidence concerns the gene TERT and glioma.